HOME> お知らせ> ATCC®ウェビナーのお知らせ


掲載日情報:2020/11/06 現在Webページ番号:66909

ATCC®(メーカー略称:ACC)では 2020年11月13日に無料のウェビナーを開催します。がん研究におけるEMT(上皮間葉転換)レポーター細胞モデルの有用性についての解説です。

・演題:EMT Reporter Models for Cancer Research: A Window into Invasion and Metastasis
・演者:Sangeeta Kumari, M.S.,(Senior Biologist, ATCC)
・開催日:2020年11月13日(金)2:00 am(日本時間)

上皮間葉転換(EMT)をリアルタイムで蛍光観察できるレポーター細胞株EMT Reporter Cell Lineシリーズについてはこちら。


Epithelial to mesenchymal transition (EMT) involves decreased cell adhesion and increased cell motility, marked by the downregulation of epithelial markers and upregulation of mesenchymal markers. Following this transition in real time can be challenging for breast cancer researchers, as in vitro EMT reporter models in mammary cell lines are not readily available. To address this need, ATCC scientists used CRISPR/Cas9 technology to engineer an EMT reporter into the MCF 10A mammary cell line. The resulting advanced model harbors a knock-in in which E-cadherin is fused with EmGFP for real-time monitoring of EMT progression. The transgene was verified at genomic DNA, transcript, and protein levels. Upon TGF-β stimulation, MCF 10A E-cadherin EmGFP shows enhanced migration, reduced E-cadherin-GFP expression, and elevated vimentin and fibronectin expression, making this engineered cell line an ideal model for screening anticancer therapeutics that target EMT.

Key takeaways:

  • ATCC scientists used CRISPR/Cas9 to engineer an E-cadherin EmGFP (ECAD-EmGFP) reporter knock-in into a breast epithelial cell line.
  • The integrity of the ECAD-EmGFP knock-in was verified at the genomic, mRNA, and protein level.
  • This advanced cancer model can be used to track EMT status of cells in vitro by monitoring GFP expression.



© 2020 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise.


(テクニカルサポート 試薬担当)